Induction of remission of relapsed acute myeloid leukemia after unrelated donor cord blood transplantation by concomitant low‐dose cytarabine and calcitriol in adults

• Published in: European journal of haematology Vol. 77; no. 4; pp. 345 - 348
• Main Authors: Yamada, Kazunari, Mizusawa, Masako, Harima, Akane, Kajiwara, Koichi, Hamaki, Tamae, Hoshi, Keiko, Kozai, Yasuji, Kodo, Hideki
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.10.2006
• Subjects: Aclarubicin - administration & dosage; Acute Disease; acute myeloid leukemia; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; calcitriol; Calcitriol - administration & dosage; Cord Blood Stem Cell Transplantation; cytarabine; Cytarabine - administration & dosage; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid - surgery; Middle Aged; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction
• ISSN: 0902-4441; 1600-0609
• DOI: 10.1111/j.0902-4441.2006.t01-1-EJH2570.x

:  Low‐dose cytarabine and calcitriol (LDCA + VD3) combination therapy was performed in two adult patients with acute myeloid leukemia (AML) that relapsed within 1 yr after unrelated donor cord blood transplantation (URD CBT) performed in a relapse or non‐remission stage. Concomitant aclarubicin was also administered in one patient. Remission because of recovery of donor cord blood hematopoiesis was obtained in both patients. The treatment was low intensive, and neither adverse effects in terms of digestive symptoms nor hypercalcemia was observed. Activity of daily life was maintained. The patients were followed as outpatients after remission, and the remission duration was approximately 6 months in both patients. Although LDCA + VD3 therapy is minimally intensive chemotherapy, it may prolong the survival time of patients with relapsed AML after URD CBT.